Clesrovimab-cfor (Enflonsia): A Comprehensive Guide to the New Monoclonal Antibody Therapy
Introduction The field of biotechnology is constantly evolving, bringing new treatment options to conditions that were once considered difficult to manage. Among these innovations, clesrovimab-cfor, marketed under the brand name Enflonsia, has emerged as a promising monoclonal antibody therapy. Designed with advanced biotechnology, clesrovimab is gaining attention in the clinical practice and research communities for …